An evaluation of sulforaphane as a potential agent for disease prevention

Research Journal of Pharmaceutical, Biological and Chemical Sciences

Volumn 5, Issue 3, 2014, Pages 1335-1349

  Alrawaiq, Nadia Salem ^a   Abdullah, Azman ^a  

^a DEPARTMENT OF PHARMACOLOGY   (Malaysia)

Author keywords

Nrf2; Phase 2 detoxifying enzymes; Sulforaphane

Indexed keywords

REACTIVE OXYGEN METABOLITE; SULFORAPHANE; TRANSCRIPTION FACTOR NRF2;

ANTIDIABETIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DIABETIC NEPHROPATHY; DRUG MECHANISM; EYE PROTECTION; HEART PROTECTION; HUMAN; KIDNEY INJURY; LIVER INJURY; NEPHROTOXICITY; NEUROPATHIC PAIN; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; SKIN PROTECTION;

EID: 84901244406     PISSN: None     EISSN: 09758585     Source Type: Journal    
DOI: None     Document Type: Article

References (91)

1. Rivera D, et al., The ethnobotanical study of local Mediterranean food plants as medicinal resources in Southern Spain. Journal of Physiology and Pharmacology. Supplement, 2005. 56 (1): p. 97-114.
2. Tapsell, L.C., et al., Health benefits of herbs and spices: the past, the present, the future. Faculty of Health and Behavioural Sciences-Papers, 2006.
3. Heinrich, M. and J.M. Prieto, Diet and healthy ageing 2100: will we globalise local knowledge systems? Ageing research reviews, 2008. 7 (3): p. 249-274.
4. Pandey, N., et al., MEDICINAL PLANTS DERIVED NUTRACEUTICALS: A RE-EMERGING HEALTH AID. International Journal of Pharma & Bio Sciences, 2011. 2 (4).
5. Heinrich, M., et al., 'Local Food-Nutraceuticals': bridging the gap between local knowledge and global needs. 2006.
6. Sánchez-Mata, M., et al., Wild vegetables of the Mediterranean area as valuable sources of bioactive compounds. Genetic Resources and Crop Evolution, 2012. 59 (3): p. 431-443.
7. Agradi, E., et al., Traditional healthy Mediterranean diet: estrogenic activity of plants used as food and flavoring agents. Phytotherapy Research, 2006. 20 (8): p. 670-675.
8. Araruna, K. and B. Carlos, Anti-inflammatory activities of triterpene lactones from Lactuca sativa. Phytopharmacol, 2010. 1 (1): p. 1-6.
9. Pereira, C., et al., Nutritional composition and bioactive properties of commonly consumed wild greens: Potential sources for new trends in modern diets. Food Research International, 2011. 44 (9): p. 2634-2640.
10. Lai, R.-H., et al., Evaluation of the safety and bioactivity of purified and semi-purified glucoraphanin. Food and Chemical Toxicology, 2008. 46 (1): p. 195-202.
11. Guerrero-Beltrán, C.E., et al., Protective effect of sulforaphane against oxidative stress: recent advances. Experimental and Toxicologic Pathology, 2012. 64 (5): p. 503-508.
12. Gan, N., et al., Sulforaphane protects Microcystin-LR-induced toxicity through activation of the Nrf2-mediated defensive response. Toxicology and applied pharmacology, 2010. 247 (2): p. 129-137.
13. Chen, J. and Z.A. Shaikh, Activation of Nrf2 by cadmium and its role in protection against cadmium-induced apoptosis in rat kidney cells. Toxicology and applied pharmacology, 2009. 241 (1): p. 81-89.
14. Wagner, A.E., et al., Sulforaphane but not ascorbigen, indole-3-carbinole and ascorbic acid activates the transcription factor Nrf2 and induces phase-2 and antioxidant enzymes in human keratinocytes in culture. Experimental dermatology, 2010. 19 (2): p. 137-144.
15. Greco, T., J. Shafer, and G. Fiskum, Sulforaphane inhibits mitochondrial permeability transition and oxidative stress. Free Radical Biology and Medicine, 2011. 51 (12): p. 2164-2171.
16. Yoon, H.-Y., et al., Sulforaphane protects kidneys against ischemia-reperfusion injury through induction of the Nrf2-dependent phase 2 enzyme. Biochemical pharmacology, 2008. 75 (11): p. 2214-2223.
17. Ahn, Y.-H., et al., Electrophilic tuning of the chemoprotective natural product sulforaphane. Proceedings of the National Academy of Sciences, 2010. 107 (21): p. 9590-9595.
18. Innamorato, N.G., et al., The transcription factor Nrf2 is a therapeutic target against brain inflammation. The Journal of Immunology, 2008. 181 (1): p. 680-689.
19. Zhao, J., et al., Enhancing expression of Nrf2-driven genes protects the blood-brain barrier after brain injury. The Journal of Neuroscience, 2007. 27 (38): p. 10240-10248.
20. Sena, L.A. and N.S. Chandel, Physiological roles of mitochondrial reactive oxygen species. Molecular cell, 2012. 48 (2): p. 158-167.
21. Alfadda, A.A. and R.M. Sallam, Reactive oxygen species in health and disease. Journal of Biomedicine and Biotechnology, 2012. 2012.
22. Kuroda, S. and B. Siesjö, Reperfusion damage following focal ischemia: pathophysiology and therapeutic windows. Clinical Neuroscience (New York, NY), 1997. 4 (4): p. 199.
23. Calabrese, V., et al., Redox regulation of cellular stress response in aging and neurodegenerative disorders: role of vitagenes. Neurochemical research, 2007. 32 (4-5): p. 757-773.
24. Kaneto, H., et al., Role of reactive oxygen species in the progression of type 2 diabetes and atherosclerosis. Mediators of inflammation, 2010. 2010.
25. Benz, C.C. and C. Yau, Ageing, oxidative stress and cancer: paradigms in parallax. Nature Reviews Cancer, 2008. 8 (11): p. 875-879.
26. Bergström, P., et al., Repeated transient sulforaphane stimulation in astrocytes leads to prolonged Nrf2-mediated gene expression and protection from superoxide-induced damage. Neuropharmacology, 2011. 60 (2): p. 343-353.
27. Vincent, A.M., et al., Sensory neurons and schwann cells respond to oxidative stress by increasing antioxidant defense mechanisms. Antioxidants & redox signaling, 2009. 11 (3): p. 425-438.
28. Mizuno, K., et al., Glutathione Biosynthesis via Activation of the Nuclear Factor E2-Related Factor 2 (Nrf2)-Antioxidant-Response Element (ARE) Pathway Is Essential for Neuroprotective Effects of Sulforaphane and 6-(Methylsulfinyl) Hexyl Isothiocyanate. Journal of pharmacological sciences, 2011. 115 (3): p. 320-328.
29. Siebert, A., et al., Nrf2 activators provide neuroprotection against 6-hydroxydopamine toxicity in rat organotypic nigrostriatal cocultures. Journal of neuroscience research, 2009. 87 (7): p. 1659-1669.
30. Vauzour, D., et al., Sulforaphane protects cortical neurons against 5-S-cysteinyl-dopamine-induced toxicity through the activation of ERK1/2, Nrf-2 and the upregulation of detoxification enzymes. Molecular nutrition & food research, 2010. 54 (4): p. 532-542.
31. Rojo, A.I., et al., Functional interference between glycogen synthase kinase-3 beta and the transcription factor Nrf2 in protection against kainate-induced hippocampal celldeath. Molecular and Cellular Neuroscience, 2008. 39 (1): p. 125-132.
32. Prochaska, H.J., A.B. Santamaria, and P. Talalay, Rapid detection of inducers of enzymes that protect against carcinogens. Proceedings of the National Academy of Sciences, 1992. 89 (6): p. 2394-2398.
33. Hong, Y., et al., The role of Nrf2 signaling in the regulation of antioxidants and detoxifying enzymes after traumatic brain injury in rats and mice. Acta Pharmacologica Sinica, 2010. 31 (11): p. 1421-1430.
34. Ping, Z., et al., Sulforaphane protects brains against hypoxic-ischemic injury through induction of Nrf2-dependent phase 2 enzyme. Brain research, 2010. 1343: p. 178-185.
35. Wierinckx, A., et al., Detoxication enzyme inducers modify cytokine production in rat mixed glial cells. Journal of neuroimmunology, 2005. 166 (1): p. 132-143.
36. Rojo, A.I., et al., Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease. Glia, 2010. 58 (5): p. 588-598.
37. Innamorato, N.G., et al., Different susceptibility to the Parkinson's toxin MPTP in mice lacking the redox master regulator Nrf2 or its target gene heme oxygenase-1. PLo S ONE, 2010. 5 (7): p. e11838.
38. Jazwa, A., et al., Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism. Antioxidants & redox signaling, 2011. 14 (12): p. 2347-2360.
39. Kim, D., et al., NADPH oxidase 2-derived reactive oxygen species in spinal cord microglia contribute to peripheral nerve injury-induced neuropathic pain. Proceedings of the National Academy of Sciences, 2010. 107 (33): p. 14851-14856.
40. Mao, L., et al., Transcription factor Nrf2 protects the spinal cord from inflammation produced by spinal cord injury. Journal of Surgical Research, 2011. 170 (1): p. e105-e115.
41. Wang, X., et al., Activation of the nuclear factor E2-related factor 2/antioxidant response element pathway is neuroprotective after spinal cord injury. Journal of Neurotrauma, 2012. 29 (5): p. 936-945.
42. Toyama, T., et al., Isothiocyanates reduce mercury accumulation via an Nrf2-dependent mechanism during exposure of mice to methylmercury. Environmental health perspectives, 2011. 119 (8): p. 1117.
43. Forbes, J.M. and M.E. Cooper, Mechanisms of diabetic complications. Physiological reviews, 2013. 93 (1): p. 137-188.
44. Brownlee, M., Biochemistry and molecular cell biology of diabetic complications. Nature, 2001. 414 (6865): p. 813-820.
45. Alpers, C.E. and K.L. Hudkins, Mouse models of diabetic nephropathy. Current opinion in nephrology and hypertension, 2011. 20 (3): p. 278.
46. Valk, E.J., J.A. Bruijn, and I.M. Bajema, Diabetic nephropathy in humans: pathologic diversity. Current opinion in nephrology and hypertension, 2011. 20 (3): p. 285-289.
47. Zheng, H., et al., Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy. Diabetes, 2011. 60 (11): p. 3055-3066.
48. Cui, W., et al., Prevention of diabetic nephropathy by sulforaphane: possible role of nrf2 upregulation and activation. Oxidative medicine and cellular longevity, 2012. 2012.
49. Voulgari, C., D. Papadogiannis, and N. Tentolouris, Diabetic cardiomyopathy: from the pathophysiology of the cardiac myocytes to current diagnosis and management strategies. Vascular health and risk management, 2010. 6: p. 883.
50. Khullar, M., et al., Oxidative stress: a key contributor to diabetic cardiomyopathy This review is one of a selection of papers published in a Special Issue on Oxidative Stress in Health and Disease. Canadian journal of physiology and pharmacology, 2010. 88 (3): p. 233-240.
51. Watanabe, K., et al., Role of differential signaling pathways and oxidative stress in diabetic cardiomyopathy. Current cardiology reviews, 2010. 6 (4): p. 280.
52. Bai, Y., et al., Prevention by sulforaphane of diabetic cardiomyopathy is associated with up-regulation of Nrf2 expression and transcription activation. Journal of molecular and cellular cardiology, 2013. 57: p. 82-95.
53. Xue, M., et al., Activation of NF-E2-related factor-2 reverses biochemical dysfunction of endothelial cells induced by hyperglycemia linked to vascular disease. Diabetes, 2008. 57 (10): p. 2809-2817.
54. Wattanapitayakul, S.K. and J.A. Bauer, Oxidative pathways in cardiovascular disease: roles, mechanisms, and therapeutic implications. Pharmacology & therapeutics, 2001. 89 (2): p. 187-206.
55. Drummond, G.R., et al., Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nature Reviews Drug Discovery, 2011. 10 (6): p. 453-471.
56. Mukherjee, S., H. Gangopadhyay, and D.K. Das, Broccoli: a unique vegetable that protects mammalian hearts through the redox cycling of the thioredoxin superfamily. Journal of agricultural and food chemistry, 2007. 56 (2): p. 609-617.
57. Angeloni, C., et al., Modulation of phase II enzymes by sulforaphane: implications for its cardioprotective potential. Journal of agricultural and food chemistry, 2009. 57 (12): p. 5615-5622.
58. Zhu, H., et al., Potent induction of total cellular and mitochondrial antioxidants and phase 2 enzymes by cruciferous sulforaphane in rat aortic smooth muscle cells: cytoprotection against oxidative and electrophilic stress. Cardiovascular toxicology, 2008. 8 (3): p. 115-125.
59. ATP channels. Pharmacological Research, 2010. 61 (4): p. 342-348.
60. Zakkar, M., et al., Activation of Nrf2 in endothelial cells protects arteries from exhibiting a proinflammatory state. Arteriosclerosis, thrombosis, and vascular biology, 2009. 29 (11): p. 1851-1857.
61. Chen, X.-L., G. Dodd, and C. Kunsch, Sulforaphane inhibits TNF-α-induced activation of p38 MAP kinase and VCAM-1 and MCP-1 expression in endothelial cells. Inflammation Research, 2009. 58 (8): p. 513-521.
62. Lin, W., et al., Sulforaphane suppressed LPS-induced inflammation in mouse peritoneal macrophages through Nrf2 dependent pathway. Biochemical pharmacology, 2008. 76 (8): p. 967-973.
63. Zheng, Y., et al., Osthole ameliorates renal ischemia-reperfusion injury in rats. Journal of Surgical Research, 2013.
64. McCord, J.M., Oxygen-derived free radicals in postischemic tissue injury. The New England Journal of Medicine, 1985. 312 (3): p. 159-163.
65. Beckman, J.K., et al., Biphasic changes in phospholipid hydroperoxide levels during renal ischemia/reperfusion. Free Radical Biology and Medicine, 1991. 11 (4): p. 335-340.
66. Hanigan, M.H. and P. Devarajan, Cisplatin nephrotoxicity: molecular mechanisms. Cancer Therapy, 2003. 1: p. 47.
67. Guerrero-Beltrán, C.E., et al., Sulforaphane protects against cisplatin-induced nephrotoxicity. Toxicology letters, 2010. 192 (3): p. 278-285.
68. Guerrero-Beltrán, C.E., et al., Protective effect of sulforaphane against cisplatin-induced mitochondrial alterations and impairment in the activity of NAD (P) H: quinone oxidoreductase 1 and gamma glutamyl cysteine ligase: studies in mitochondria isolated from rat kidney and in LLC-PK1 cells. Toxicology letters, 2010. 199 (1): p. 80-92.
69. Shin, D.-H., et al., The NRF2-heme oxygenase-1 system modulates cyclosporin A-induced epithelial-mesenchymal transition and renal fibrosis. Free Radical Biology and Medicine, 2010. 48 (8): p. 1051-1063.
70. Bowler, R.P. and J.D. Crapo, Oxidative stress in allergic respiratory diseases. Journal of Allergy and Clinical Immunology, 2002. 110 (3): p. 349-356.
71. Boldogh, I., et al., ROS generated by pollen NADPH oxidase provide a signal that augments antigen-induced allergic airway inflammation. Journal of Clinical Investigation, 2005. 115 (8): p. 2169-2179.
72. Riedl, M.A., A. Saxon, and D. Diaz-Sanchez, Oral sulforaphane increases Phase II antioxidant enzymes in the human upper airway. Clinical immunology, 2009. 130 (3): p. 244-251.
73. Ritz, S.A., J. Wan, and D. Diaz-Sanchez, Sulforaphane-stimulated phase II enzyme induction inhibits cytokine production by airway epithelial cells stimulated with diesel extract. American Journal of Physiology-Lung Cellular and Molecular Physiology, 2007. 292 (1): p. L33-L39.
74. Liu, L.-P., et al., The protective effects of Polygonum multiflorum stilbeneglycoside preconditioning in an ischemia/reperfusion model of HUVECs. Acta Pharmacologica Sinica, 2010. 31 (4): p. 405-412.
75. Giakoustidis, A.E., et al., Inhibition of intestinal ischemia/repurfusion induced apoptosis and necrosis via down-regulation of the NF-κ B, c-Jun and caspace-3 expression by epigallocatechin-3-gallate administration. Free radical research, 2008. 42 (2): p. 180-188.
76. Li, C. and R.M. Jackson, Reactive species mechanisms of cellular hypoxia-reoxygenation injury. American Journal of Physiology-Cell Physiology, 2002. 282 (2): p. C227-C241.
77. Zhao, H.-D., et al., Sulforaphane protects liver injury induced by intestinal ischemia reperfusion through Nrf2-ARE pathway. World journal of gastroenterology: WJG, 2010. 16 (24): p. 3002.
78. Lii, C.-K., et al., Sulforaphane and a-lipoic acid upregulate the expression of the pi class of glutathione S-transferase through c-Jun and Nrf2 activation. The Journal of nutrition, 2010. 140 (5): p. 885-892.
79. Narmada, B., et al., HSC-targeted delivery of HGF transgene via bile duct infusion enhances its expression at fibrotic foci to regress DMN-induced liver fibrosis. Human gene therapy, 2013.
80. Lichtinghagen, R., et al., The Enhanced Liver Fibrosis (ELF) Score: Normal Values, Influence Factors and Proposed Cut-OffValues. Journal of hepatology, 2013.
81. Sekiguchi, H., et al., Culture on a Fragmin/Protamine-Coated Plate Suppresses the Collagen Type IaI and TGF-β1 mRNA Expression of Rat Hepatic Stellate RI-T Cells. The Journal of veterinary medical science/the Japanese Society of Veterinary Science, 2012.
82. Bopp, A., et al., Rac1 modulates acute and subacute genotoxin-induced hepatic stress responses, fibrosis and liver aging. Cell death & disease, 2013. 4 (3): p. e558.
83. Oh, C.J., et al., Sulforaphane attenuates hepatic fibrosis via NF-E2-related factor 2-mediated inhibition of transforming growth factor-β/Smad signaling. Free Radical Biology and Medicine, 2012. 52 (3): p. 671-682.
84. Sancho-Pelluz, J., et al., Photoreceptor cell death mechanisms in inherited retinal degeneration. Molecular neurobiology, 2008. 38 (3): p. 253-269.
85. Schwartz, S.D., et al., Embryonic stem cell trials for macular degeneration: a preliminary report. The Lancet, 2012. 379 (9817): p. 713-720.
86. Gao, X., A.T. Dinkova-Kostova, and P. Talalay, Powerful and prolonged protection of human retinal pigment epithelial cells, keratinocytes, and mouse leukemia cells against oxidative damage: the indirect antioxidant effects of sulforaphane. Proceedings of the National Academy of Sciences, 2001. 98 (26): p. 15221-15226.
87. Gao, X. and P. Talalay, Induction of phase 2 genes by sulforaphane protects retinal pigment epithelial cells against photooxidative damage. Proceedings of the National Academy of Sciences of the United States of America, 2004. 101 (28): p. 10446-10451.
88. Tanito, M., et al., Sulforaphane induces thioredoxin through the antioxidant-responsive element and attenuates retinal light damage in mice. Investigative ophthalmology & visual science, 2005. 46 (3): p. 979-987.
89. Kong, L., et al., Delay of photoreceptor degeneration in tubby mouse by sulforaphane. Journal of neurochemistry, 2007. 101 (4): p. 1041-1052.
90. Liu, H., et al., Sulforaphane can protect lens cells against oxidative stress: implications for cataract prevention. Investigative ophthalmology & visual science, 2013. 54 (8): p. 5236-5248.
91. Kleszczynski, K., et al., Sulforaphane and phenylethyl isothiocyanate protect human skin against UVR-induced oxidative stress and apoptosis: Role of Nrf2-dependent gene expression and antioxidant enzymes. Pharmacological Research, 2013. 78: p. 28-40.